menu
    • menu
    [{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"6","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabinol","moa":"cannabinol derivatives","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CAS 492-27-3","moa":"Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 2A; Aryl hydrocarbon receptor; G-protein coupled receptor 35","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II\/ Phase III","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Cream","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"9","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Astaxanthin","moa":"NF-kappa-B inhibitor alpha","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Kirin Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Cognizin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Alpha-GPC","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Arrabina P Prebiotic","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Bacillus Subtilis ATCC 122264","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bioplete","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Collagen Peptide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Digestive Enzyme Blend","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"8","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Inulinase","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Bonafide Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"JDS-HF","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KH-1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Korean Red Ginseng Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Potato Starch","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"11","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TPG1","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"},{"orgOrder":0,"company":"Nutrasource","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutrasource","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrasource \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Nutrasource \/ Nutrasource"}]

    Find Clinical Drug Pipeline Developments & Deals by Nutrasource

    Menu

    Nutrasource

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Digestive Enzyme Blend

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Recipient : Pancap Pharma Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial on Digestive Enzymes: Effects on Post-Meal Response to High-Fat, High-Protein Meals

                            Details : Digestive Enzyme Blend is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            April 29, 2025

                            Lead Product(s) : Digestive Enzyme Blend

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Recipient : Pancap Pharma Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Potato Starch

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Recipient : MSP Starch Products Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study on the Effects of Resistant Potato Starch on Gut Bacteria in Healthy Adults

                            Details : Potato Starch is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            April 29, 2025

                            Lead Product(s) : Potato Starch

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Recipient : MSP Starch Products Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagen Peptide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Recipient : Rousselot BVBA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Assess the Effect of Collagen on Gastrointestinal Discomfort in Healthy Adults With Gastrointestinal Sympto...

                            Details : Collagen Peptide is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastrointestinal Diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 22, 2025

                            Lead Product(s) : Collagen Peptide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Recipient : Rousselot BVBA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cognizin

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Kirin Holdings

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Effects of Citicoline on Cognitive Performance in Healthy Adults

                            Details : Cognizin is a drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 02, 2025

                            Lead Product(s) : Cognizin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Kirin Holdings

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arrabina P Prebiotic

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Recipient : Comet Bio Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Placebo-Controlled Study Evaluating the Effects of Arrabina P on Satiety in Healthy Adults

                            Details : Arrabina P Prebiotic is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Weight Control.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 19, 2025

                            Lead Product(s) : Arrabina P Prebiotic

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Recipient : Comet Bio Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAS 492-27-3

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II/ Phase III

                            Recipient : Birch BioMed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients

                            Details : Kynurenic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Burn Scar.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2025

                            Lead Product(s) : CAS 492-27-3

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Birch BioMed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TPG1

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Recipient : Standard Process Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Safety of a Bovine Thymus Nucle...

                            Details : TPG1 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Allergy and Immunology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 28, 2025

                            Lead Product(s) : TPG1

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Recipient : Standard Process Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Royal DSM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted C...

                            Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 29, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Royal DSM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ascorbic Acid

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Royal DSM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pharmacokinetic Study of Single Oral Doses of Six Different Vitamin C Product Forms

                            Details : Vitamin C is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 24, 2024

                            Lead Product(s) : Ascorbic Acid

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Royal DSM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nutrasource

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KH-1

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Recipient : Kalin Health, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of KH-1 for Stimulating Autophagy in Non-diabetic Adults With Elevated Blood Glucose Conce...

                            Details : KH-1 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Prediabetic State.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 06, 2024

                            Lead Product(s) : KH-1

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Recipient : Kalin Health, LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth